



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
-----------------	-------------	----------------------	---------------------	------------------

10/815,340

03/30/2004

Jay A. Berzofsky

015280-368240US

8261

45115

7590

02/03/2009

TOWNSEND AND TOWNSEND AND CREW, LLP  
TWO EMBARCADERO CENTER  
8TH FLOOR  
SAN FRANCISCO, CA 94111

EXAMINER

KINSEY WHITE, NICOLE ERIN

ART UNIT

PAPER NUMBER

1648

MAIL DATE

DELIVERY MODE

02/03/2009

PAPER

**Please find below and/or attached an Office communication concerning this application or proceeding.**

The time period for reply, if any, is set in the attached communication.

<b>Office Action Summary</b>	<b>Application No.</b> 10/815,340	<b>Applicant(s)</b> BERZOFSKY ET AL.	
	<b>Examiner</b> NICOLE KINSEY WHITE	<b>Art Unit</b> 1648	

**-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --**

**Period for Reply**

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

**Status**

- 1) ☒ Responsive to communication(s) filed on 11 December 2008.
- 2a) ☐ This action is **FINAL**.                      2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

**Disposition of Claims**

- 4) ☒ Claim(s) 1,3-14,25-35,70 and 71 is/are pending in the application.
- 4a) Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- 6) ☒ Claim(s) 1,3-14,25-35,70,71 is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_\_ is/are objected to.
- 8) ☐ Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

**Application Papers**

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_\_ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

**Priority under 35 U.S.C. § 119**

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All    b) ☐ Some \*    c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

**Attachment(s)**

- |  |   |
|--|---|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892)                     | 4) <input type="checkbox"/> Interview Summary (PTO-413)           |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | Paper No(s)/Mail Date. _____                                      |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08)          | 5) <input type="checkbox"/> Notice of Informal Patent Application |
| Paper No(s)/Mail Date _____  | 6) <input type="checkbox"/> Other: _____                          |

### **DETAILED ACTION**

A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicants' submission filed on December 11, 2008 has been entered.

### ***Claim Rejections - 35 USC § 103***

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

Claims 1, 3, 4, and 25 remain rejected under 35 U.S.C. 103(a) as being unpatentable over Klavinskis et al. (J. of Immunol., 1996, 157:2521-2527) and either Ahlers et al. (J. of Immunol., 1997, 158:3947-3958) or Berzofsky et al. (WO 94/26785). This rejection is withdrawn against claims 15, 16, 21, and 23 in view of applicants' cancellation of claims 15-24.

The claims are drawn to a method for inducing a protective rectal mucosal cytotoxic T lymphocyte (CTL) response in a mammalian subject comprising contacting a rectal mucosal tissue of the subject with a composition comprising a chimeric peptide having the amino acid sequence of SEQ ID NO:9.

Klavinskis et al. teaches rectal and vaginal immunization by administering an SIV peptide antigen covalently linked to cholera toxin B subunit (CTB). CTB was used as an adjuvant. See page 2522 – Immunization schedule. Klavinskis et al. showed that CTLs were isolated from the rectal mucosa and were antigen-specific (see page 2524).

Klavinskis et al. does not teach SEQ ID NO:9 or an antigen from HIV-1 or administering the antigen without an adjuvant. However, both Ahlers et al. and Berzofsky et al. disclose the peptide of SEQ ID NO:9 (see page 3948 of Ahlers et al. and SEQ ID NO:28 and claim 15 of Berzofsky et al.). Both references describe the peptide of SEQ ID NO:9 as being derived from HIV-1, as an inducer of cytotoxic T cells, and useful for therapeutic or prophylactic vaccines against HIV.

It would have been obvious to one of ordinary skill in the art to modify the method taught by Klavinskis et al. to administer the peptide of SEQ ID NO:9 to a subject. One would have been motivated to do so given the suggestion by Klavinskis et al. that to

prevent dissemination of HIV to the regional lymph nodes, an effective vaccine may need to stimulate CTL in the rectal or genital tract (see abstract and introduction). Further, given that the rectal route is a recognized major route for HIV transmission and given that there is a recognized need in the art to raise a mucosal immune response at the site of transmission, it would have been obvious to administer an antigen/construct to the rectal mucosa in order to reduce transmission. One also would have been motivated by the teachings of Ahlers et al. and Berzofsky et al. (SEQ ID NO:9 contains an immunodominant HIV CTL epitope). There would have been a reasonable expectation of success given the findings of Klavinskis et al. that mucosal or targeted lymph node immunization generates antigen-specific CTL in the rectal and genital mucosa.

As for the use of adjuvants, Klavinskis et al. teaches the use of cholera toxin as an adjuvant. However, it is known in the art that immune responses can be induced with or without adjuvants. Thus, it is well within the purview of one of ordinary skill in the vaccine arts to administer an antigen with or without an adjuvant.

Thus, the invention as a whole was clearly *prima facie* obvious to one of ordinary skill in the art at the time the invention was made.

### ***Response to Arguments***

In the reply dated December 11, 2008, applicants argue that the claimed invention is directed to administering antigen to only colorectal tissue; whereas, Klavinskis et al. discloses rectal or vaginal administration followed by three oral

administrations of the vaccine. This argument and the Declaration under 37 C.F.R. §1.132 have been fully considered, but not found persuasive.

In Klavinskis et al., at the time of administering the antigen to mucosal tissue, rectal or colorectal mucosal tissue was the only site of administration. The oral administrations were carried out months after the rectal administration. Applicants' claims, as currently amended, do not eliminate further antigen administrations at a later time in the future via another route or the same route. Applicants' newly added limitation merely describes what happens at a particular point in time (i.e., at first exposure to the antigen), but does not address what may happen later. According to the claims, at the time of antigen administration (or first exposure to the antigen), the antigen is administered to colorectal tissue only. Klavinskis et al. teaches this also. Klavinskis et al. goes on to teach oral administrations at monthly intervals (at least 30 days after the first exposure of antigen to rectal mucosa).

Claims 1, 5-14, 25-35 remain rejected under 35 U.S.C. 103(a) as being unpatentable over Klavinskis et al. and either Ahlers et al. (J. of Immunol., 1997, 158:3947-3958) or Berzofsky et al. (WO 94/26785) as applied to claims 1, 3, 4, 25 above and further in view of Kiyono et al. (Advanced Drug Delivery Reviews, 18: 23-51).

The claims are drawn to a method for inducing a protective rectal mucosal cytotoxic T lymphocyte (CTL) response in a mammalian subject comprising contacting a rectal mucosal tissue of the subject with a composition comprising a purified soluble

Art Unit: 1648

antigen, wherein the method further comprises administering a purified cytokine, e.g., GM-CSF, IL-2, IL-7, IL-12, IFN- $\gamma$  or TNF- $\alpha$ , to the subject.

The teachings of Klavinskis et al. are outlined above. Klavinskis et al. does not teach administering a cytokine to the subject. However, Ahlers et al. teaches immunizing a subject with the peptide of SEQ ID NO:9 and various cytokines (GM-CSF, IL-2, IL-12, IFN- $\gamma$  or TNF- $\alpha$ ). Ahlers et al. found that GM-CSF synergized with IL-12 for CTL induction. TNF- $\alpha$  also synergized with IL-12, but by a different mechanism, inducing IFN- $\gamma$  production, thus shifting the response to a Th1 phenotype (see abstract). Ahlers et al. suggests that in addition to IL-2, optimum induction of CD8+ CTL *in vivo* requires a combination of cytokines, including GM-CSF and IL-12 (steering the Th response toward Th1 cytokines) (see the abstract and the Results section on page 3949).

It would have been obvious to one of ordinary skill in the art to modify the method taught by Klavinskis et al. to also administer cytokines to the subject with the antigen. One would have been motivated to do so given the suggestion by Kiyono et al. that Th cell-derived cytokines are essential for the induction of appropriate antigen-specific mucosal immune responses (see bottom of page 23) and the teachings of Ahlers et al. There would have been a reasonable expectation of success given the findings of Ahlers et al. with regard to CTL induction by cytokines. Thus, the invention as a whole was clearly *prima facie* obvious to one of ordinary skill in the art at the time the invention was made.

### ***Response to Arguments***

In the reply dated December 11, 2008, applicants argue, *inter alia*, that the activity of cytokine after administration to a colorectal mucosal surface was surprising because the cytokine maintained activity even after being exposed to bacterial proteases which are found in the colon. This argument as well as the Declaration under 37 C.F.R. § 1.132 are not found persuasive.

Cytokines, like the antigen being administered, are proteins. It is not clear how applicants, or one of ordinary skill in the art, would expect the protein antigen to survive in the colon and maintain its function (e.g., successfully immunize the subject), but the same is not true for the cytokine, which is also a protein. To the contrary, based on the teachings of Klavinskis et al., protein antigens can be administered rectally to a subject and result in some degree of protection and CTL induction. Therefore, it seems reasonable to believe that a cytokine, which is also a protein, could also be administered with the expectation of enhancing the immune response.

No claim is allowed.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to NICOLE KINSEY WHITE whose telephone number is (571)272-9943. The examiner can normally be reached on Monday through Friday from 9:00 am to 5:30 pm.



If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Bruce Campell can be reached on (571) 272-0974. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Nicole Kinsey White/  
Examiner, Art Unit 1648

/Stacy B Chen/  
Primary Examiner, Art Unit 1648